Last reviewed · How we verify
Piperacillin, Tazobactam Drug Combination
Piperacillin inhibits bacterial cell wall synthesis while tazobactam inhibits beta-lactamase enzymes, allowing piperacillin to kill a broader spectrum of bacteria including beta-lactamase-producing organisms.
Piperacillin inhibits bacterial cell wall synthesis while tazobactam inhibits beta-lactamase enzymes, allowing piperacillin to kill a broader spectrum of bacteria including beta-lactamase-producing organisms. Used for Bacterial infections in pediatric patients (including intra-abdominal, skin and soft tissue, and respiratory tract infections), Febrile neutropenia in pediatric cancer patients.
At a glance
| Generic name | Piperacillin, Tazobactam Drug Combination |
|---|---|
| Also known as | piperacillin-tazobactam, Zosyn |
| Sponsor | Phoenix Children's Hospital |
| Drug class | Beta-lactam antibiotic with beta-lactamase inhibitor |
| Target | Penicillin-binding proteins (PBPs); beta-lactamase enzymes |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Piperacillin is a broad-spectrum beta-lactam antibiotic that binds to penicillin-binding proteins and disrupts bacterial cell wall cross-linking. Tazobactam is a beta-lactamase inhibitor that irreversibly binds and inactivates beta-lactamase enzymes produced by resistant bacteria, preventing degradation of piperacillin and extending its spectrum of activity against otherwise resistant gram-negative and gram-positive organisms.
Approved indications
- Bacterial infections in pediatric patients (including intra-abdominal, skin and soft tissue, and respiratory tract infections)
- Febrile neutropenia in pediatric cancer patients
Common side effects
- Diarrhea
- Nausea and vomiting
- Rash
- Allergic reactions
- Clostridium difficile-associated diarrhea
Key clinical trials
- Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia (PHASE4)
- A Randomised Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients. (PHASE4)
- Subcutaneous Piperacillin/Tazobactam Compared With Intravenous Treatment (PHASE2)
- SYN-004 Safety and Tolerability in Allo-HCT Subjects (PHASE1, PHASE2)
- Evaluation of the Achievement of a Pharmacodynamic Target of Piperacillin-Tazobactam for the Population With Obesity (PHASE4)
- Aminoglycosides in Early Sepsis (PHASE4)
- Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial (NA)
- Choosing the Best Antibiotic to Protect Friendly Gut Bacteria During the Course of Stem Cell Transplant (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: